Accepted Manuscript

Nationwide Study on Peripheral Venous Catheter Associated–Bloodstream Infections in Internal Medicine Departments

María Guembe, PharmD, PhD, María Jesús Pérez-Granda, RN, PhD, José Antonio Capdevila, MD, PhD, José Barberán, MD, PhD, Blanca Pinilla, MD, PhD, Pablo Martín-Rabadán, MD, DTMH, Emilio Bouza, MD, PhD, Jesús Millán, Carlos Pérez de Oteyza, Antonio Muiño, Mariví Villalba, Carmen Cuenca, Jesús García Castaño, Cecilia Muñoz Delgado, Sonia Zamorano, Beatriz Gómez, José Manuel Collado, Miguel Torres Salinas, Alex Smithson Amat, Javier Ramos Lázaro, Valentín del Villar Sordo, Mario del Valle Sánchez, Ángela Felip Benach, Elena Vidal, Laia Albiach, José Manuel Agud Aparicio, Esther Saéz de Adana Arroniz, Jordi Casademont i Pou, Virginia Pomar Solchaga, Fernando Escolar Castellón, Teresa Rubio Obanos, Maria Victoria Egurbide Arberas, Javier Nieto Arana, Eduardo García López, Antonio Zapatero Gaviria, Ivan Navas Clemente, Paula Cuenca Ruíz, Antonio Castro Salomó, Simona Micaela Iftimie, Antonio Martín Castillo, José Ramón Barberá Farré, Amat Ortí Lavería, Mercé Cardona Ribera, Naya Bellaubí Pallarés, Pedro Cancelo Suárez, Francisco Javier Cepeda Piorno, Noelia Arenal Andrés, Raquel Elisa Rodríguez Tarazona, Manuel Miguel Rodríguez Zapata, María Asunción Costa Cerdá

PII: S0195-6701(17)30390-0

DOI: 10.1016/j.jhin.2017.07.008

Reference: YJHIN 5163

To appear in: Journal of Hospital Infection

Received Date: 23 March 2017

Revised Date: 0195-6701 0195-6701

Accepted Date: 4 July 2017

Please cite this article as: Guembe M, Pérez-Granda MJ, Capdevila JA, Barberán J, Pinilla B, Martín-Rabadán P, Bouza E, on behalf of the NUVE Study Group, Millán J, Pérez de Oteyza C, Muiño A, Villalba M, Cuenca C, Castaño JG, Delgado CM, Zamorano S, Gómez B, Collado JM, Salinas MT, Amat AS, Lázaro JR, Sordo VdV, Sánchez MdV, Benach ÁF, Vidal E, Albiach L, Aparicio JMA, Arroniz ESdA, Casademont i Pou J, Solchaga VP, Castellón FE, Obanos TR, Egurbide Arberas MV, Arana JN, López EG, Gaviria AZ, Clemente IN, Ruíz PC, Salomó AC, Iftimie SM, Castillo AM, Barberá Farré JR, Lavería AO, Ribera MC, Pallarés NB, Suárez PC, Piorno FJC, Andrés NA, Tarazona RER, Zapata MMR, Cerdá



MAC, Nationwide Study on Peripheral Venous Catheter Associated–Bloodstream Infections in Internal Medicine Departments, *Journal of Hospital Infection* (2017), doi: 10.1016/j.jhin.2017.07.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

- 1 Nationwide Study on Peripheral Venous Catheter Associated–Bloodstream Infections in
- 2 Internal Medicine Departments
- 3 María Guembe^{1,4}, PharmD, PhD
- 4 María Jesús Pérez-Granda^{3,4,6}, RN, PhD
- 5 José Antonio Capdevila^{5,7}, MD, PhD
- 6 José Barberán^{5,8}, MD, PhD
- 7 Blanca Pinilla^{5,9}, MD, PhD
- 8 Pablo Martín-Rabadán^{1,2,3,4}, MD, DTMH
- 9 Emilio Bouza^{1,2,3,4,5}, MD, PhD on behalf of the NUVE Study Group
- ¹⁰ ¹ Department of Clinical Microbiology and Infectious Diseases, Hospital General
- 11 Universitario Gregorio Marañón, Madrid, Spain
- ² Medicine Department, School of Medicine, Universidad Complutense de Madrid,
- 13 Madrid, Spain
- ¹⁴ ³ CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain
- ⁴ Instituto de Investigación Sanitaria Gregorio Marañón (IISGM)
- ¹⁶ ⁵ Study Group of Infections of the Sociedad Española de Infecciones Cardiovasculares
- 17 (SEICAV)
- ⁶ Cardiac Surgery Postoperative Care Unit, Hospital General Universitario Gregorio
- 19 Marañón, Madrid, Spain
- ²⁰ ⁷ Department of Internal Medicine, Hospital de Mataró, Barcelona, Spain
- ⁸ Department of Internal Medicine, Hospital de Montepríncipe, Madrid, Spain
- ⁹ Department of Internal Medicine, HGU Gregorio Marañón, Madrid, Spain
- 23 Running title: "Peripheral Catheter–Bloodstream Infections"

- 24 **Corresponding author:**
- 25 María Guembe, PharmD, PhD
- 26 Servicio de Microbiología Clínica y Enfermedades Infecciosas
- 27 Hospital General Universitario "Gregorio Marañón"
- 28 C/. Dr. Esquerdo, 46
- 29 28007 Madrid, Spain
- 30 Phone: +34- 91- 586 80 27
- 31 Fax: +34- 91- 586 87 67
- 32 E-mail: mariaguembe@hotmail.com

33 SUMMARY

Background. The use of peripheral venous catheters (PVCs) has increased outside the intensive care unit, as have rates of peripheral venous catheter associated-bloodstream infection (PVC-BSI). The internal medicine department (IMD) is one of the main wards where PVCs are widely used. However, data on the incidence of PVC-BSI and its characteristics in the IMD are scarce.

Aim. Our objective was to assess the incidence of PVC-BSI episodes detected in IMDs in
Spain.

Methods. We performed a 1-year multicenter prospective observational cohort study in
14 Spanish IMDs. We included adult patients admitted with at least one PVC and
bacteremia. Demographic and clinical data were provided by local coordinators.

Findings. We recorded 70 episodes of PVC-BSI, representing an overall rate of 1.64 PVC-BSI episodes/1,000 IMD admissions. Patients had a mean (SD) age of 67.44 (16.72) years. It was estimated that 25.7% of PVCs were no longer necessary. *Staphylococcus aureus* was the most frequently isolated microorganism (41.7%). Phlebitis was clinically evident in 44 (62.9%) episodes and proved to be an independent predictor of catheter insertion in emergency departments (OR=5.44). The crude and attributable mortality rates were 12.9% and 5.7%, respectively.

51 **Conclusion**. Our study shows that PVCs carry a significant risk for bacteremia in Spanish 52 IMDs. Phlebitis is not always clinically evident in patients with bacteremia in this 53 population. Our findings support the need for educational and interventional preventive 54 measures both in IMDs and in emergency departments to reduce the rate of PVC-BSI and 55 associated comorbidities and costs.

Keywords: peripheral venous catheter; bacteremia; *Staphylococcus aureus*; prevalence;
 phlebitis; peripheral venous catheter-associated bloodstream infection; internal
 medicine departments.

60 **INTRODUCTION**

61 Central venous catheter (CVC)–related bloodstream infections are one of the 62 most common types of nosocomial infection and are associated with high rates of 63 morbidity and mortality (1, 2). Data on these infections come mainly from intensive care 64 unit patients, where CVCs account for only 4.6% to 18.1% of all catheters used (3-5).

Peripheral venous catheters (PVCs) have become increasingly used in recent years. In addition, exposure to PVCs has become more prolonged, thus leading to an increase in the number of episodes of PVC-associated bloodstream infections (PVC-BSI) (3, 6-13). Rates of PVC-RBSI in Spain have been described between 0.11 and 0.18 PVC-BSI episodes/1,000 admissions (8, 9). Internal medicine departments (IMDs) care for severely ill elderly patients in whom PVCs are widely used (3). However, data on the presence of PVC-BSI and its characteristics in this particular population are scarce.

72

Our objective was to assess the incidence of PVC-BSI detected in IMDs in Spain.

- 73 **METHODS**
- 74 Setting

We performed a multicenter prospective observational cohort study in 14 Spanish
 IMDs from June 2015 to June 2016. Table 1 shows details of the participating centers.

77 Inclusion criteria

Adult patients (>18 years) admitted to the IMD with at least 1 PVC and significant
 bloodstream infection due to the PVC (PVC-BSI).

80 Data collection and analysis

81 The demographic and clinical data obtained from the local coordinator for each 82 patient and catheter were as follows: age, sex, Charlson comorbidity index, severity of

	sepsis, phlebitis, septic complications (septic metastasis, renal failure), days of antibiotic
84	therapy, extra days of hospitalization, mortality, catheter tip culture, catheter indwelling
85	time, catheter insertion site, location of catheter insertion, need for a catheter, and use
86	of needleless connectors. Surveillance was monitored from the diagnosis of significant
87	bloodstream infection until catheter withdrawal.
88	All centers followed the standard recommendations collected in pocket leaflets
89	regarding the prevention of infection during catheter insertion and maintenance
90	(supplemental data file).
91	All withdrawn catheter tips were included in the analysis, regardless of whether
92	they were sent for culture or not (despite this being a requirement in the study).
93	Definitions
	Devine have ly an any extension (DV(C)) Cathering the extension of C2 are (2 in chas)
94	Peripheral venous catheter (PVC). Catheter shorter than 7.62 cm (3 inches).
94 95	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which
94 95 96	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which those pathogens were present in ≥ 1 blood cultures. We considered commensal
94 95 96 97	<i>Significant bloodstream infection</i> . Episode of bacteraemia or fungaemia, in which those pathogens were present in \geq 1 blood cultures. We considered commensal microorganisms [coagulase negative Staphylococci (CNS), <i>Corynebacterium</i> sp. (except <i>C</i> .
94 95 96 97 98	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which those pathogens were present in ≥1 blood cultures. We considered commensal microorganisms [coagulase negative Staphylococci (CNS), Corynebacterium sp. (except C. jeikeium), Lactobacillus sp., Bacillus sp. and Propionibacterium sp., or viridans group
94 95 96 97 98 99	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which those pathogens were present in ≥1 blood cultures. We considered commensal microorganisms [coagulase negative Staphylococci (CNS), Corynebacterium sp. (except C. jeikeium), Lactobacillus sp., Bacillus sp. and Propionibacterium sp., or viridans group Streptococcus isolates and C. perfringens] as probable pathogens when they were
 94 95 96 97 98 99 100 	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which those pathogens were present in \geq 1 blood cultures. We considered commensal microorganisms [coagulase negative Staphylococci (CNS), Corynebacterium sp. (except C. jeikeium), Lactobacillus sp., Bacillus sp. and Propionibacterium sp., or viridans group Streptococcus isolates and C. perfringens] as probable pathogens when they were recovered in \geq 2 blood cultures. Practices to perform blood cultures were all based on
 94 95 96 97 98 99 100 101 	Significant bloodstream infection. Episode of bacteraemia or fungaemia, in which those pathogens were present in ≥ 1 blood cultures. We considered commensal microorganisms [coagulase negative Staphylococci (CNS), Corynebacterium sp. (except C. jeikeium), Lactobacillus sp., Bacillus sp. and Propionibacterium sp., or viridans group Streptococcus isolates and C. perfringens] as probable pathogens when they were recovered in ≥ 2 blood cultures. Practices to perform blood cultures were all based on international guidelines recommendations and samples obtained through the catheter

103 *Sepsis*. The systemic response to infection, manifesting as 2 or more of the 104 following conditions as a result of infection: temperature >38°C or <36°C; heart rate >90

beats per minute; respiratory rate >20 breaths per minute or $PaCO_2$ <32 mm Hg; and white blood cell count >12,000 mm³, <4,000 mm³, or >10% immature (band) forms (15).

107 *Severe sepsis*. Sepsis associated with organ dysfunction, hypoperfusion, or 108 hypotension. Hypoperfusion and perfusion abnormalities may include, but are not 109 limited to, lactic acidosis, oliguria, or an acute alteration in mental status (15).

Septic shock. Sepsis with hypotension despite adequate fluid resuscitation along with perfusion abnormalities that may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in mental status. Patients receiving inotropic or vasopressor agents may not be hypotensive at the time perfusion abnormalities are measured (15).

Phlebitis. Presence of 1 or more of the following criteria: swelling and erythema
>4 mm, tenderness, palpable venous cord, and pain or fever with local symptoms.
Isolated swelling is not defined as phlebitis.

118 *PVC-BSI*. Presence of positive peripheral blood cultures from a patient with a PVC 119 and clinical manifestations of infection (fever, chills, and/or hypotension) and no 120 apparent source of infection other than the PVC.

121 *Microbiological confirmation of PVC-BSI*. Isolation of the same microorganism 122 both in the colonized PVC tip and in blood cultures obtained through a peripheral vein 123 (14).

Peripheral venous catheter colonization. Positivity of the PVC tip culture by the
 roll-plate technique (≥15 cfu/plate) (14).

126 An episode of 'significant' bloodstream infection was defined as an episode of 127 bacteremia or fungemia, in which those pathogens were present in \ge 1 blood cultures.

We considered commensal microorganisms (coagulase negative Staphylococci [CNS], *Corynebacterium* sp. [except *C. jeikeium*], *Lactobacillus* sp., *Bacillus* sp., and *Propionibacterium* sp., or *viridans* group *Streptococcus* isolates and *C. perfringens*) as probable pathogens when they were recovered in ≥ 2 blood cultures.

132 Statistical analysis

Normally distributed continuous variables were compared using the *t* test; nonnormally distributed variables were compared using the Mann-Whitney test, median test, or Kruskal-Wallis test. Categorical variables were evaluated using the chi-squared or 2-tailed Fisher exact test.

Values for continuous variables are expressed as the mean (SD) or median (interquartile range, IQR) and as percentages, with a 95% confidence interval (95% CI), when applicable, for categorical variables. A 2-tailed test was used to determine statistical significance, which was set at p<0.05.

We compared PVC-BSI episodes caused by *Staphylococcus aureus* with those caused by other microorganisms and between PVC-BSI episodes with and without phlebitis. The multivariate analysis included variables that showed statistically significant differences between the groups compared in the univariate analysis. For the multivariate analysis, we used binary logistic regression and incorporated variables found to be significant (p<0.1) in the univariate analysis. The statistical analysis was performed using PASW Statistics for Windows (SPSS Inc, 18.0, Chicago, Illinois, USA).

148 Ethics

149 This study was approved by the local ethics committee of Hospital Gregorio 150 Marañón. Written informed consent was obtained from all patients included in the study.

151 **RESULTS**

The 14 IMDs were mainly in teaching institutions (71.4%), and 21.4% were in institutions with \geq 500 beds. During the study period, the 14 institutions admitted 302,779 patients, 42,577 of whom were sent to the IMD (**Table 1**). We collected a total of r0 episodes of PVC-BSI from 70 patients, corresponding to 1.64 PVC-BSI episodes/1,000 IMD admissions. This represented approximately 0.28 episodes/1,000 catheter days of exposure based on previous studies of our group in which we reported that >85% of the hospitalized patients had at least 1 venous line for a median of 7 days (4, 5).

159 **Patients and catheters**

Patients had a mean (SD) age of 67.44 (16.72) years and 60.0% were men. The 160 mean (SD) comorbidity index (Charlson) was 5.5 (3.25). The median (IQR) catheter 161 indwelling time was 6 (4-12) days, and only 19 catheters (27.1%) had been inserted for 162 ≤96 hours. Most PVCs were inserted in the arm (34.3%), followed by the elbow flexure 163 (25.7%) and the back of the hand (8.6%). The insertion site of the remaining 22 PVCs 164 165 (31.4%) was not specified. As for department of insertion, 26 PVCs (37.1%) were inserted in the emergency department, and only 21 (30.3%) were inserted in hospital or surgical 166 wards. The department of the remaining 23 (32.3%) PVCs was unknown. The catheter 167 insertion site had been checked 24 hours before the PVC-BSI episode in 75.7% of 168 patients, and 55.7% of the PVCs were closed with needleless connectors. Only 20 (28.6%) 169 170 of the PVC tips were withdrawn before or at the time of the diagnosis of the PVC-RSI 171 episode. It was estimated that 25.7% of the PVCs in place were no longer necessary on the day of the study (Table 2). Phlebitis was observed in 62.9% of cases, and purulence 172 173 was present in 5 catheters (7.1%).

174	Of the 70 episodes of PVC-BSI, 52 (74.3%) involved sepsis, whereas 25.7%
175	involved severe sepsis or septic shock. Septic metastasis and/or renal failure was
176	recorded in 14.3% of cases. Patients were under antibiotic therapy for a median (IQR) of
177	13.00 (7.00-16.25) days. The crude mortality and the attributable mortality rates were
178	12.9% and 5.7%, respectively (Table 2).

179 Etiology of PVC-BSI episodes

The distribution of the microorganisms isolated in the 70 PVC-BSI episodes was as follows: Gram-positive, 87.5%; Gram-negative, 11.1%; and yeasts, 1.4%. *Staphylococcus aureus* was the most frequently isolated microorganism (41.7%), followed by *Staphylococcus epidermidis* and other coagulase-negative staphylococci (CoNS) (28.5%) (**Table 3**). Among the 38 episodes of *S. aureus* bacteremia, 8 (21.1%) were caused by methicillin-resistant *S. aureus* (MRSA). There were only 2 (2.9%) polymicrobial PVC-BSI episodes.

Only 37 (52.9%) out of the 70 CVC tips were sent for culture. Of them, 26 (70.3%) corresponded to microbiologically confirmed PVC-BSI episodes. The distribution of the 28 microorganisms isolated in the positive PVC tips was as follows: *S. aureus*, 42.9% (26.7% MRSA); *S. epidermidis* and CoNS, 25.0%; *Enterococcus faecalis*, 10.7%; *Klebsiella pneumoniae*, 10.7%; *Pseudomonas aeruginosa*, 7.1%; and *Candida albicans*, 3.6%.

192 Risk factors for *S. aureus* PVC-BSI and phlebitis in the study population

When we compared the distribution of the study variables for the 70 PVC-SBI episodes between infection caused by *S. aureus* and infection caused by other agents, we did not find any statistically significant differences except for duration of antimicrobial therapy, which was longer for *S. aureus* (p<0.001) (**Table 4**).

197 When we compared the distribution of the study variables according to the presence or absence of phlebitis, we found that the independent risk factors for phlebitis 198 were shorter catheter indwelling time, longer time on antimicrobial therapy, catheter 199 200 withdrawal before or at the time of the PVC-BSI episode, and catheter insertion in the emergency department (p<0.001, p=0.026, p=0.01, and p=0.004, respectively). In the 201 multivariate analysis (which included only catheter days, age, catheter insertion in the 202 emergency department, and idle catheters), we found that insertion of the PVC in the 203 emergency department had an odds ratio (OR) of 5.44 (95% CI, 1.54-19.30; p=0.009) for 204 phlebitis. We also detected that, despite the absence of statistical significance, 50% of 205 the catheters that were no longer necessary were associated with phlebitis (p=0.19) 206 (Table 4). 207

208 **DISCUSSION**

Our data showed that PVC-BSI is a major problem in Spanish IMDs, with an incidence rate of 1.64 episodes/1,000 IMD admissions and *S. aureus* as the causative agent in 41.7% of episodes. Phlebitis was not present in 37.1% of the episodes. We also found that many catheters were no longer necessary during the study period.

PVCs have been increasingly used during the last few years, mainly outside ICUs (11), thus leading to an increase in the number of PVC-BSI episodes. In Spain, rates of 0.11 and 0.18 PVC-BSI episodes/1,000 admissions were found in 2 teaching institutions (8, 9). Lower rates were reported in a multicenter study in which the PVC-BSI rate was 0.05 episodes/1,000 patient-days (16). In IMDs in particular, data on the estimated frequency of PVC-BSI are lacking. In the present study, we found the PVC-BSI rate to be

219 1.64 episodes/1,000 IMD admissions and an estimation of 0.28 PVC-BSI episodes/1,000 220 catheter-days, ie, significantly higher than that previously reported for whole institutions. The mean age of the patients in our study was >65 years, and this has been 221 222 associated with higher rates of morbidity and mortality, particularly in patients with S. aureus bacteremia (17). Our attributable mortality rate was 5.7%, although follow-up 223 was not long. A recent study found that 85% of patients aged ≥65 years died within 5 224 years (18). We showed that most PVC-BSI episodes were caused by S. aureus (41.7%), as 225 reported by other authors (9, 16, 19-21). However, we did not find any risk factors 226 associated with S. aureus PVC-BSI. We only found a significant difference between S. 227 aureus PVC-BSI and non-S. aureus PVC-RBSI regarding the days of antimicrobial therapy 228 (43.01 vs. 26.58 days, p<0.001). 229

The rate of phlebitis (62.9%) was surprisingly low, as might be expected in this 230 bacteremic population, thus supporting the observation that phlebitis is not a good 231 marker for bacteremia. We also demonstrated that phlebitis was not associated with 232 233 longer catheter indwelling times, in contrast with reports from other authors (22) and in support of previous recommendations not to replace PVCs every 96 hours (23-26). It has 234 been hypothesized that phlebitis is more frequent in PVCs as a result of chemical 235 irritation of the vein wall by the substances administered and that risk is higher when the 236 course and calibre of the vein are lower, as this facilitates contact perfusion with the 237 238 vascular endothelium (10, 27). The most important finding was that 22 of the 26 239 catheters (84.6%) from bacteremic patients that had been inserted in the emergency department were associated with phlebitis, with an OR of 5.44 of phlebitis among 240 catheters that were inserted in the emergency department (p=0.009), as also shown in 241

242	whole hospital populations (12, 28). These findings strongly support adherence to the
243	recommendation to insert catheters under aseptic conditions or replace them in <48 h if
244	aseptic conditions are not followed during insertion. The same recommendations for
245	central venous catheters should also be applied in PVCs (29).
246	Another important issue in the management of PVCs was the rate of idle
247	catheters. Several studies showed rates of 16% to 38% in both CVCs and PVCs (3, 11, 30).
248	We found that 25.1% of the PVCs were no longer necessary, thus implying that future
249	preventive measures to reduce the number of unnecessary PCVs should include daily
250	monitoring of catheter use based on a check-list, as performed with CVCs (26, 29).
251	Of note, 47.1% of the withdrawn PVC tips were not sent for culture, despite this
252	being a study requirement. This shortcoming should be considered in future

recommendations for the management of PVC-BSI, and physicians should be encouraged to send the tip for culture to confirm the PVC-BSI episode (26). Moreover, 11 (29.7%) of the 37 cultured PVC tips were negative, thus PVC-BSI episodes could not be microbiologically confirmed.

Finally, the 70 PVC-BSI episodes were a major problem in the IMD not only because of their related comorbidities, but also because they represented an extra cost of \pounds 1,060,570 in the 14 institutions. The question of cost was recently assessed in a Spanish study in which the authors estimated that the extra cost of an episode of bacteremia was \pounds 15,151 (31).

The main limitation of this study is that our data can only be extrapolated to bacteremic older patients admitted mainly to IMDs from hospitals with <500 beds.

Our findings demonstrate that PVC-BSI is still a major problem in IMDs and that introducing mandatory educational and interventional preventive measures is essential, if we are to reduce the frequency of PVC-BSI and associated comorbidities and overall costs (29, 32).

269 **ACKNOWLEDGEMENTS**

- 270 We thank Thomas O'Boyle for his help in the preparation of the manuscript.
- 271 We thank the members of the NUVE study group for their contribution to the study:
- 272 Hospital General Universitario Gregorio Marañón (Madrid): Jesús Millán, Carlos Pérez de
- 273 Oteyza, Antonio Muiño, Mariví Villalba, Carmen Cuenca, Jesús García Castaño, Cecilia
- 274 Muñoz Delgado, Sonia Zamorano, Beatriz Gómez, José Manuel Collado.
- 275 Hospital L'Esperit Sant (Cataluña): Miguel Torres Salinas, Alex Smithson Amat, Javier
- 276 Ramos Lázaro.
- 277 Hospital de Santa Bárbara (Castilla La Mancha): Valentín del Villar Sordo, Mario del Valle
- 278 Sánchez.
- 279 Hospital de Mataró (Cataluña): Ángela Felip Benach, Elena Vidal, Laia Albiach.
- Hospital de Txagorritxu (País Vasco): José Manuel Agud Aparicio, Esther Saéz de Adana
 Arroniz.
- Hospital Santa Creu i Sant Pau (Cataluña): Jordi Casademont i Pou, Virginia Pomar
 Solchaga.
- Hospital Reina Sofía (Navarra): Fernando Escolar Castellón, Teresa Rubio Obanos.
- Hospital Universitario de Cruces (País Vasco): Maria Victoria Egurbide Arberas, Javier
- 286 Nieto Arana, Eduardo García López.
- Hospital Universitario de Fuenlabrada (Madrid): Antonio Zapatero Gaviria, Ivan Navas
 Clemente, Paula Cuenca Ruíz.
- Hospital Universitario Sant Joan de Reus (Cataluña): Antonio Castro Salomó, Simona
 Micaela Iftimie.

291	Hospital General La Mancha Centro (Castilla La Mancha): Antonio Martín Castillo, José
292	Ramón Barberá Farré.
293	Hospital de Tortosa Verge de la Cinta (Cataluña): Amat Ortí Lavería, Mercé Cardona
294	Ribera, Naya Bellaubí Pallarés.
295	Hospital Santos Reyes (Burgos): Pedro Cancelo Suárez, Francisco Javier Cepeda Piorno,
296	Noelia Arenal Andrés, Raquel Elisa Rodríguez Tarazona.
297	Hospital Universitario de Guadalajara (Castilla La Mancha): Manuel Miguel Rodríguez
298	Zapata, María Asunción Costa Cerdá.
299	
300	Potential conflicts of interest. The authors declare no conflicts of interest.
300 301	Potential conflicts of interest. The authors declare no conflicts of interest.
300 301 302	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN,
300301302303	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, CP13/00268) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII),
 300 301 302 303 304 	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, CP13/00268) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain. The study was partially funded by the European Regional Development
 300 301 302 303 304 305 	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, CP13/00268) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain. The study was partially funded by the European Regional Development Fund (FEDER) "A way of making Europe" and Fundación Española de Medicina Interna
 300 301 302 303 304 305 306 	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, CP13/00268) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain. The study was partially funded by the European Regional Development Fund (FEDER) "A way of making Europe" and Fundación Española de Medicina Interna (FEMI).
 300 301 302 303 304 305 306 307 	Potential conflicts of interest. The authors declare no conflicts of interest. Financial support: M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, CP13/00268) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid Spain. The study was partially funded by the European Regional Development Fund (FEDER) "A way of making Europe" and Fundación Española de Medicina Interna (FEMI).

REFERENCES

1. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. Jama 1994;271(20):1598-601.

2. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005;41(11):1591-8.

3. Guembe M, Perez-Granda MJ, Capdevila JA, et al. Nationwide study on the use of intravascular catheters in internal medicine departments. J Hosp Infect 2015;90(2):135-41.

4. Perez-Granda MJ, Guembe M, Rincon C, Munoz P, Bouza E. Effectiveness of a training program in compliance with recommendations for venous lines care. BMC Infect Dis 2015;15:296.

5. Perez-Granda MJ, Guembe MR, Rincon C, Munoz P, Bouza E. A prevalence survey of intravascular catheter use in a general hospital. J Vasc Access 2014;15(6):524-8.

6. Kallen AJ, Patel PR, O'Grady NP. Preventing catheter-related bloodstream infections outside the intensive care unit: expanding prevention to new settings. Clin Infect Dis 2010;51(3):335-41.

7. Gozu A, Clay C, Younus F. Hospital-wide reduction in central line-associated bloodstream infections: a tale of two small community hospitals. Infect Control Hosp Epidemiol 2011;32(6):619-22.

8. Delgado-Capel M, Gabillo A, Elias L, Yebenes JC, Sauca G, Capdevila JA. [Peripheral venous catheter-related bacteremia in a general hospital]. Rev Esp Quimioter 2012;25(2):129-33.

9. Pujol M, Hornero A, Saballs M, et al. Clinical epidemiology and outcomes of peripheral venous catheter-related bloodstream infections at a university-affiliated hospital. J Hosp Infect 2007;67(1):22-9.

10. Capdevila JA. [Use of peripheral catheters: too much to learn]. Rev Esp Quimioter 2013;26(1):1-5.

11. Alexandrou E, Ray-Barruel G, Carr PJ, et al. International prevalence of the use of peripheral intravenous catheters. J Hosp Med 2015;10(8):530-3.

12. Lee WL, Chen HL, Tsai TY, et al. Risk factors for peripheral intravenous catheter infection in hospitalized patients: a prospective study of 3165 patients. Am J Infect Control 2009;37(8):683-6.

13. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006;81(9):1159-71.

14. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.

15. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55.

16. Freixas N, Bella F, Limon E, Pujol M, Almirante B, Gudiol F. Impact of a multimodal intervention to reduce bloodstream infections related to vascular catheters in non-ICU wards: a multicentre study. Clin Microbiol Infect 2013;19(9):838-44.

17. Yahav D, Schlesinger A, Shaked H, et al. Clinical presentation, management and outcomes of Staph aureus bacteremia (SAB) in older adults. Aging Clin Exp Res 2016.

18. Yahav D, Yassin S, Shaked H, et al. Risk factors for long-term mortality of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2016;35(5):785-90.

19. Stuart RL, Cameron DR, Scott C, et al. Peripheral intravenous catheterassociated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services. Med J Aust 2013;198(10):551-3.

20. Yilmaz M, Elaldi N, Balkan, II, et al. Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study. Ann Clin Microbiol Antimicrob 2016;15:7.

21. Austin ED, Sullivan SB, Whittier S, Lowy FD, Uhlemann AC. Peripheral Intravenous Catheter Placement Is an Underrecognized Source of Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis 2016;3(2):ofw072.

22. Cicolini G, Manzoli L, Simonetti V, et al. Phlebitis risk varies by peripheral venous catheter site and increases after 96 hours: a large multi-centre prospective study. J Adv Nurs 2014;70(11):2539-49.

23. Webster J, Osborne S, Rickard CM, New K. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev 2015(8):CD007798.

24. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet 2012;380(9847):1066-74.

25. Tan GY, Tai WL, Sim C, Ng HL. Optimizing peripheral venous catheter usage in the general in-patient ward: A prospective observational study. J Clin Nurs 2016.

26. Capdevila JA, Guembe M, Barberan J, et al. 2016 Expert consensus document on prevention, diagnosis and treatment of short-term peripheral venous catheterrelated infections in adult. Rev Esp Quimioter 2016;29(4):230-8.

27. Tagalakis V, Kahn SR, Libman M, Blostein M. The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. Am J Med 2002;113(2):146-51.

28. Mestre G, Berbel C, Tortajada P, et al. Successful multifaceted intervention aimed to reduce short peripheral venous catheter-related adverse events: a quasiexperimental cohort study. Am J Infect Control 2013;41(6):520-6.

29. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52(9):e162-93.

30. Parenti CM, Lederle FA, Impola CL, Peterson LR. Reduction of unnecessary intravenous catheter use. Internal medicine house staff participate in a successful quality improvement project. Arch Intern Med 1994;154(16):1829-32.

31. Riu M, Chiarello P, Terradas R, et al. Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona. PLoS One 2016;11(4):e0153076.

32. Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2014;86 Suppl 1:S1-70.

ON-LINE SUPPLEMENTARY FIGURE 1: Pocket leaflet describing the prevention of

infection during catheter insertion and maintenance

Table 1. Description of the participating institutions

N=14	
Teaching institution, N (%)	10 (71.4)
Public institution, N (%)	13 (82.9)
<500 beds, N (%)	11 (78.6)
Mean (SD) population	223,376.6 (110,022.7)
Mean (SD) no. of hospital admissions/2014 (>24 h)	21,627.1 (14,772.0)
Mean (SD) no. of IMD admissions/2014 (>24 h)	3,041.2 (1,453.3)
Mean (SD) total no. of hospital beds	409.1 (296.2)
Mean (SD) total no. of beds in the IMD	67.6 (25.4)
Mean (SD) days of hospital stay	7.9 (1.1)

SD, standard deviation; **IMD**, internal medicine department.

Table 2. Patient and catheter data for the PVC-BSI episodes

Characteristic	N (%)
Patients (N=70)	
Mean (SD) age, years	67.44 (16.72)
Male sex	42 (60.0)
Mean (SD) comorbidity index (Charlson)	5.5 (3.25)
Type of infection	
Sepsis	52 (74.3)
Severe sepsis	17 (24.3)
Septic shock	1 (1.4)
Complications	
None	60 (85.7)
Septic metastasis	6 (8.6)
Renal failure	2 (2.9)
> 1 complication	2 (2.9)
Median (IQR) days of antibiotic therapy	13 (7.00-16.25)
Crude mortality	9 (12.9)
Attributable mortality	4 (5.7)
Catheters (N=70)	
Microbiological culture	
Positive	26/37 (70.3)
Negative	11/37 (29.7)

Non-cultured	33/70 (47.1)
Median (IQR) catheter days	6 (4-12)
Catheter indwelling time	
≤96 hours	19 (27.1)
>96 hours	51 (72.9)
Insertion site	
Right elbow flexure	11 (15.7)
Left elbow flexure	7 (10.0)
Right arm	14 (20.0)
Left arm	10 (14.3)
Back of the right hand	4 (5.7)
Back of the left hand	2 (2.9)
Other	22 (31.4)
Department where catheter was inserted	
Emergency	26 (37.1)
Hospital ward	17 (24.3)
Surgery	4 (5.7)
Other	23 (32.3)
Catheter insertion site revised at least 24 hours before PVC-BSI episode	53 (75.7)

Phlebitis	44 (62.9)
Purulence	5 (7.1)
Use of needleless connectors	39 (55.7)
Use of disinfectable needleless connectors	35/39 (89.7)
Time of catheter withdrawal	
Before or at the same time of PVC-BSI episode	20 (28.6)
After PVC-BSI episode	50 (71.4)
No. of idle catheters	18 (25.7)

SD, standard deviation; **IQR**, interquartile range; **ICU**, intensive care unit; **PVC-BSI**, peripheral venous catheter associated–bloodstream infection.

Table 3. Microorganisms isolated in the PVC-BSI episodes

Microorganism	N (%)
Gram +	63 (87.5)
Methicillin-susceptible Staphylococcus aureus	30 (41.7)
Methicillin-resistant Staphylococcus aureus	8 (11.1)
Staphylococcus epidermidis	14 (19.4)
CNS	6 (8.3)
Enterococcus faecalis	4 (5.6)
Propionibacterium acnes	1 (1.4)
Gram –	8 (11.1)
Klebsiella pneumoniae	4 (5.6)
Pseudomonas aeruginosa	3 (4.2)
Escherichia coli	1 (1.4)
Yeasts	1 (1.4)
Candida albicans	1 (1.4)

CNS, coagulase-negative staphylococci.

Table 4. Risk factors for *S. aureus* PVC-BSI and phlebitis

Variable	SAB	No SAB	р	Phlebitis	No phlebitis	р
	N=38	N=32		N=44	N=26	
Median (IQR) days of antimicrobial therapy	14.50 (11.75-21.50)	8.00 (7.00-14.00)	<0.001	14.00 (10.00-19.50)	9.50 (7.00-15.25)	0.02
Median (IQR) catheter days	6.00 (4.00-9.00)	7.00 (4.25-14.75)	0.27	5.00 (4.00-7.00)	12.00 (6.00-24.00)	<0.001
Catheter indwelling time, N (%)			0.71			0.005
≤96 hours (N=19)	11 (28.9%)	8 (25.0%)		17 (38.6%)	2 (7.7%)	
>96 hours (N=51)	27 (71.1%)	24 (75.0%)		27 (61.4%)	24 (92.3%)	
Time of catheter withdrawal, N (%)			0.94			0.01
Before or at the same time of PVC-BSI episode (N=20)	11 (28.9%)	9 (28.1%)		36 (81.8%)	14 (53.8%)	
After PVC-BSI episode (N=50)	27 (71.1%)	23 (71.9%)		8 (18.2%)	12 (46.2%)	
Septic complications, N (%)			0.70			0.61
One or more (N=10)	6 (15.8%)	4 (12.5%)		7 (15.9%)	3 (11.5%)	
None (N=60)	32 (84.2%)	28 (87.5%)		37 (84.1%)	23 (88.5%)	
Attributable mortality, N (%)	2 (5.3%)	2 (6.3%)	0.63	1 (2.3%)	3 (11.6%)	0.14

Severe sepsis or septic shock (N=18), N (%)	13 (34.2%)	5 (15.6%)	0.08	12 (27.3%)	6 (23.1%)	0.70
Phlebitis (N=44), N (%)	27 (71.1%)	17 (53.1%)	0.12	NA	NA	NA
Catheter insertion in emergency department (N=26), N (%)	17 (44.4%)	9 (28.1%)	0.15	22 (50.0%)	4 (15.4%)	0.004
Idle catheters (N=18), N (%)	11 (28.9%)	7 (21.9%)	0.50	9 (20.5%)	9 (34.6%)	0.19

IQR, interquartile range; SAB, Staphylococcus aureus bacteremia; PVC-BSI, peripheral venous catheter associated-bloodstream infection; NA,

not applicable.

Jureus bactere...